Outspoken researcher Peter Bach urges CMS to consider ways of bringing down CAR-T prices — and offers a few suggestions
When it comes to determining coverage for expensive — but potentially lifesaving — CAR-T therapies, CMS doesn’t have to roll over and let drugmakers dominate the conversation. The agency, instead, should leverage competition to bring down the cost of these still-imperfect meds.
That’s according to Peter Bach, the director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes in New York. Known for often speaking out on drug pricing, Bach detailed his thoughts on the matter in a paper published in The New England Journal of Medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.